Published in J Surg Oncol on October 01, 2008
Nestin: a novel angiogenesis marker and possible target for tumor angiogenesis. World J Gastroenterol (2013) 1.03
Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J Transl Med (2009) 1.00
Antiangiogenic therapies for advanced hepatocellular carcinoma. Oncologist (2013) 0.94
Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist (2012) 0.90
Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci (2014) 0.89
Tumor suppressor XAF1 induces apoptosis, inhibits angiogenesis and inhibits tumor growth in hepatocellular carcinoma. Oncotarget (2014) 0.88
HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. Oncotarget (2016) 0.81
Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment. World J Hepatol (2015) 0.80
Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis. Med Sci Monit (2015) 0.79
Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival. World J Hepatol (2015) 0.79
Recombinant soluble gp130 protein reduces DEN-induced primary hepatocellular carcinoma in mice. Sci Rep (2016) 0.77
Downregulation of miRNA-638 promotes angiogenesis and growth of hepatocellular carcinoma by targeting VEGF. Oncotarget (2016) 0.76
Evaluation of microvessel density of hepatocellular carcinoma and comparison with benign lesions of liver: an immunohistochemical study. Iran Red Crescent Med J (2012) 0.75
Molecular targeting of VEGF/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. Cancer Biol Ther (2017) 0.75
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58
Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med (2002) 6.20
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int (2011) 3.69
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol (2013) 3.45
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst (2008) 3.27
Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis (2012) 3.22
Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst (2009) 3.19
Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan. Hepatology (2014) 2.79
Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology (2008) 2.46
Clinical characteristics and prognostic factors of splenic abscess: a review of 67 cases in a single medical center of Taiwan. World J Gastroenterol (2006) 2.41
Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. Am J Gastroenterol (2010) 2.32
miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid (2010) 2.30
Kikuchi's disease: a review and analysis of 61 cases. Otolaryngol Head Neck Surg (2003) 2.29
Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. Eur Urol (2008) 2.24
Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology (2007) 2.20
Living donor liver transplantation: the Asian perspective. Transplantation (2014) 2.13
Ultrafine titanium dioxide particles in the absence of photoactivation can induce oxidative damage to human bronchial epithelial cells. Toxicology (2005) 2.12
Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol (2003) 2.09
Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer (2003) 2.09
Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol (2013) 2.06
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol (2006) 2.03
Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer (2006) 1.92
Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology (2010) 1.89
Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol (2010) 1.88
Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology (2005) 1.81
Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology (2008) 1.81
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology (2010) 1.79
Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res (2005) 1.77
The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. Eur J Cancer (2008) 1.71
Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology (2010) 1.69
Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J Hepatol (2010) 1.67
Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study. Liver Int (2009) 1.65
Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol (2003) 1.63
Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. Liver Int (2008) 1.63
A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology (2006) 1.62
Angioleiomyoma originating from the ovary of an eleven-year-old premenarchal girl. Gynecol Obstet Invest (2008) 1.62
Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol (2006) 1.62
Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol (2013) 1.60
Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology (2011) 1.59
Clinical implications of alpha-fetoprotein in chronic hepatitis C. J Formos Med Assoc (2009) 1.57
Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol (2005) 1.55
Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol (2004) 1.55
Endoscopic papillary balloon dilation for removal of bile duct stones: evaluation of outcomes and complications in 298 patients. J Clin Gastroenterol (2012) 1.55
Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol (2005) 1.54
Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. Int J Cancer (2007) 1.54